Office-use compounding in New Jersey

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

Human office useHigh confidence

Prohibited for sterile and non-sterile alike, subject only to a federal-law escape clause — and § 353a does not open one, because it conditions the compounding exemptions on a patient-specific prescription.

Veterinary / non-humanHigh confidence

Permitted without a prescription, consistent with state and federal law.

Batch preparationHigh confidence

13:39-11.17(b) — a pharmacy "shall not batch prepare compounded sterile preparations for human use without a prescription for a licensed prescriber to use in his or her practice, except to the extent permitted by Federal law."

Anticipatory batching for patientsHigh confidence

Permitted (13:39-11.17(a), 13:39-11A.5) on a documented history of valid prescriptions generated solely within an established prescriber-patient-pharmacist relationship, with unique batch numbers, documented drug, container and diluent lots and expirations, and visual inspection for particulates and leakage.

Quantity capHigh confidence

None stated — moot, since the activity is barred.

Sterile compounding approvalHigh confidence

Sterile compounding requires application and pre-approval by the Board (13:39-11.3).

New Jersey at a glance

Receiving 503B office stock in New Jersey

New Jersey is the one state reviewed here where we cannot tell you which credential the facility needs. No outsourcing-facility category exists, and the rule everyone reaches for does not reach a 503B. Read the sourcing note on every item below before relying on any of it.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What New Jersey asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inLow confidence

Unsettled, and nothing here should be treated as a compliance instruction. New Jersey has no outsourcing-facility registration category, and N.J.A.C. 13:39-4.20(a) reaches only a pharmacy shipping "pursuant to a prescription" — which fails twice for a facility shipping non-patient-specific office stock. The best reading is a wholesale distributor registration with the Department of Health under N.J.S.A. 24:6B and N.J.A.C. 8:21-3A. Confirm with the Division of Consumer Affairs and the Department of Health.A search of the New Jersey rules returns a single "503(b)" hit and it is a false friend: N.J.A.C. 8:21-3A.3 uses the FDCA legend-drug provision, which has nothing to do with outsourcing facilities. Anyone searching New Jersey law for "503" will hit it and misreport it.

Does your practice need a permit?Medium confidence

None identified for non-controlled stock — and that is the honest phrasing, not "none exists". No facility-level permit surfaced in the pharmacy, controlled-dangerous- substance or wholesale-distribution chapters, but the Board of Medical Examiners chapter (N.J.A.C. 13:35) was not crawled and a receiving-practice duty could live there.

Administer vs dispenseMedium confidence

Physician dispensing is capped at a seven-day supply, at or below cost plus ten per cent, under N.J.S.A. 45:9-22.11. Administering in the office is not dispensing and the cap does not reach it.The statute excepts "allergenic extracts and injectables", and New Jersey has never construed how far that exception reaches. How it applies to compounded injectable office stock is the low-confidence part of this item.

Scheduled (controlled) stockHigh confidence

A hard yes, per location. N.J.A.C. 13:45H-1.2(c) requires registration of "every person who dispenses (including prescribing, administering, compounding, or delivering)" a controlled dangerous substance, with a separate registration "for each place of business or professional practice". The only office exemption, 13:45H-1.3(h)2, covers an office where substances are prescribed "provided that no such substances are administered, delivered, or otherwise dispensed, and no such substances are contained in such office" — so it collapses by its own terms the moment scheduled stock sits on site.

How to check a facility’s credential before you order is set out in how to place an office-use order.

What this page does not establish

• The rule text quoted under "Receiving 503B office stock in New Jersey" comes from Cornell LII rather than from the January 2025 archive capture that sources the rest of this page, because the archive host was unreachable when that section was researched. Cornell LII publishes no "current through" date, so we are confident in the words and less confident that they are the operative text today. Open the official chapter PDF in a browser and check its footer revision date before relying on that section.
• New Jersey’s Division of Consumer Affairs blocks automated access, so the official chapter PDF behind this page came from a January 2025 web-archive capture whose own footer reads "Last Revision Date: 5/20/2024". We are confident in the quoted text and less confident that it remains the operative text today. Check that footer date in an ordinary browser before relying on it.
• New Jersey’s active-rulemaking database could not be queried, so pending New Jersey rulemaking is outside what this page covers.
• New Jersey’s practitioner-dispensing rules are outside the scope of this page; we have not checked them.